StreetAlpha.app
Home › Stocks › AKBA

Akebia Therapeutics, Inc. (AKBA)

Healthcare
$0.40
▼ −10.74%
LAST CLOSE · NOV 17

Akebia develops and sells kidney disease medicines, including the anemia treatment Vafseo and the phosphorus control drug Auryxia. It last closed at $0.40 on Nov 17, down 10.74% on the day. The average 12-month price target from 4 analysts is $3.38 (+742.9% from the last close), with a high of $4.50 and a low of $2.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is AKBA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$197.2M
−12.4% vs a year ago
Net income
−$44.6M
−22.6% margin
EPS (diluted)
−$0.17
Free cash flow
$13.9M
7.0% margin
Valuation
Market cap
$111.2M
277.7M shares
P/E
–
No P/E while losing money
Price to sales
0.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$159.3M
At Sep 30
Debt
$50.3M
At Sep 30
Shareholder equity
$20.4M
Shares outstanding
277.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $211.7M$211.7MFY2021FY2022: $292.5M$292.5MFY2022FY2023: $194.6M$194.6MFY2023FY2024: $160.2M$160.2MFY2024FY2025: $236.2M$236.2MFY2025

From AKBA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on AKBA in the past 90 days
Average 12-month target
$3.38
▲ 742.9% upside

Based on 4 analysts who set a price target on AKBA in the past 90 days. The average target is $3.38, with a high of $4.50 and a low of $2.00, compared with the last close of $0.40.

Low $2.00Avg $3.38High $4.50
Blue marker: last close $0.40
Highest target$4.50
Average target$3.38
Lowest target$2.00
Latest rating changes
Piper SandlerMaintained
Nov 16Buy$2
HC Wainwright & Co.Target lowered
Nov 6Buy$6 → $4
BTIGMaintained
Nov 5Buy$3
WestPark CapitalInitiated
Sep 8Buy$4.50
Leerink PartnersDowngrade
Aug 8Hold$1
DateFirmActionRatingPrice target
Nov 16Piper SandlerMaintainedBuy$2
Nov 6HC Wainwright & Co.Target loweredBuy$6 → $4
Nov 5BTIGMaintainedBuy$3
Sep 8WestPark CapitalInitiatedBuy$4.50
Aug 8Leerink PartnersDowngradeHold$1
Loading…

Technical Analysis

AKBA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 46% below its 20 day and 87% below its 50 day average. It is 173% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $0.38, and the nearest resistance the Pivot at $0.41.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 17.8%/day
Key levels
$1.8452 week high+360.0%
$1.09200 day average+172.5%
$0.94100 day average+135.0%
$0.7550 day average+87.5%
$0.5820 day average+45.0%
$0.58Swing high (Nov 11)+45.0%
$0.44Pivot R1+10.0%
$0.41Pivot+2.5%
$0.40Last close
$0.38Pivot S1−5.0%
$0.3652 week low−10.0%
$0.36Swing low (Nov 6)−10.0%
Indicators
RSI (14)32.46Weak, oversold below 30Neutral
MACD-0.09Below its signal lineBearish
Stochastic18.2Near the bottom of its rangeOversold
ADX (14)27.3Trending down
Williams %R-91.1Oversold below −80, overbought above −20Oversold
CCI (20)-116.0Oversold below −100, overbought above 100Oversold
Rate of change−44.8%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 17.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AKBA

What happened before

See how AKBA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AKBA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AKBA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AKBA in the last 90 days.

Loading…

See today’s whale options flow across the market →

AKBA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼59 buying vs 97 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding156170−8.2%
In funds' top 1000–
Held by funds39.2%39.6%−0.4 pts
New / increased22 / 3736 / 69−43.8%
Reduced / sold out58 / 3933 / 36+40.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AKBA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKBA is in one of them and how their past AKBA trades turned out.

AKBA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AKBA in an article yet. Here's the latest on the wider market.

About Akebia Therapeutics

Akebia is a biopharmaceutical company based in Waltham, Massachusetts, that develops and sells medicines for people with kidney disease. Its main product, Vafseo, is an oral treatment for anemia caused by chronic kidney disease in adults on dialysis. Its second product, Auryxia, is an oral medicine used to control phosphorus levels in dialysis patients and to treat iron deficiency anemia in adults with kidney disease who are not on dialysis. The company also develops treatments for rare kidney conditions.

Headquarters
Waltham, MA